ArticleNPJ vaccines2026
β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
Multidrug-resistant fungi, Candida auris, persist in the healthcare environment and colonize human skin and medical devices, causing life-threatening infections with mortality rates approaching ~60% in immunocompromised patients. Because some isolates are resistant to nearly all available antifungal drugs, alternative therapeutic approaches are urgently needed. C. auris cell wall contains β-glucan and highly conserved fungal glycan structures. Moreover, many cell wall proteins are heavily β-glycosylated, and a monoclonal antibody raised against β-glucan has been shown to recognize C. albicans hyphal-regulated cell wall protein (Hyr1p), which has homologous proteins in C. auris. Based on this conversation, we evaluated β-glucan chitosan particles (GCP) as a vaccine candidate and evaluated the humoral and cellular immune responses. GCP induced robust IgG antibody and IFN-γ, IL-4, and IL17 producing T cells that recognized purified C. auris cell wall proteins. Anti-GCP antibodies recognized the cell walls of C. auris isolates from four phylogenetic clades through binding to cell wall glycoproteins. Mice vaccinated with GCP were protected from disseminated C. auris infection (40% vs. 0% survival, p = <0.0001). GCP-vaccinated mice had significantly lower fungal burden than placebo in target organs (kidney, heart, and brain) and fewer fungal abscesses. These findings support GCP vaccination as a promising strategy against MDR C. auris.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.